Intellipharmaceutics International Inc. (IPCI)

[Tekterra]

Yeah, I find that surprising he assign zero value to Rexista. He's logic was that big players are taking the market shares and Rexista would be at a disadvantage enter much later. But, I don't think he realize Rexista is likely superior to those products already out, assuming FDA panel review is positive things can change in favor of IPCI. I do like how success rate was at above 80% but that's just based on other drug approval history.

So we have a good chance to see at least a tentative approval on Rexista.